A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications (10-CBA)

A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (10-106)

Continuation of a previously approved retrospective review, and a proposal to open a Propsective Registry for patients treated with the Xoft Axxent System device to track safety, efficacy, and cosmetic outcomes in patients with basal and squamous cell cancers.

A Phase Ib/II Study Evaluating The Safety And Efficacy Of Obinutuzumab In Combination With Polatuzumab Vedotin And Venetoclax In Patients With Relapsed Or Refractory Follicular Lymphoma And Rituximab In Combination With Polatuzumab Vedotin And Venetoclax In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients with Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma

An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

A Phase 3, Double-Blind, Placebo-Controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

A Phase 1 Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous PF-06747143, Administered as Single Agent or in Combination with Standard Chemotherapy in Adult Patients with Acute Myeloid Leukemia

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

A Phase 3 Open-Label, Randomized, Multicenter Study Of Nktr-102 Versus Treatment Of Physician¿s Choice (Tpc) In Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases And Have Been Previously Treated With An Anthracycline, A Taxane, And Capecitabine

An Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize theEffects of a Moderate CYP3A Inhibitor on the Pharmacokinetics of Tazemetostat (EPZ-6438) (Part A), the Effects of Tazemetostat on the Pharmacokinetics of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on the Pharmacokinetics of Tazemetostat (Part B) in Subjects with B-cell Lymphomas or Advanced Solid Tumors

A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination with
Trametinib and Dabrafenib in Subjects with Advanced Melanoma
To evaluate the efficacy with respect to progression-free survival (PFS) of
MK-3475 administered intravenously in combination with oral dabrafenib and
trametinib in subjects with advanced (unresectable or metastatic) melanoma with
BRAF V600 E or K mutations, compared with placebo administered intravenously in
combination with oral dabrafenib and trametinib alone.

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

A Phase 2, Multicenter, Multi-Cohort, Open-Label Study of Pomalidomide in Combination with Low-Dose Dexamethasone or Pomalidomide in Combination with Low-Dose Dexamethasone and Daratumumab in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide-Based Therapy in the First or Second Line Setting

A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma

A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

CA209651: An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

A Phase I/II, Open-label, 2 Arm Study to Investigate the Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of GSK2879552 Administered Alone or in Combination With Azacitidine, in Adult Subjects With IPSS-R High and Very High Risk Myelodysplastic Syndromes (MDS) Previously Treated With Hypomethylating Agents (HMA)

Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery

A retrospective study on the outcome of patients with genitourinary (GU) malignancies who were treated at Dignity Health St. Joseph's Hospital and Medical Center (including University of Arizona Cancer Center at Dignity Health St. Joseph's)

A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 (PD-1), AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES, IN PATIENTS WITH ADVANCED MALIGNANCIES